FDA Approves Moderna’s mFlusiva, First mRNA Flu Vaccine

Overview

• The FDA approved Moderna’s mFlusiva on Thursday, Aug. 6, 2026, giving full authorization for adults 50 to 64 and accelerated approval for people 65 and older that requires confirmatory post‑marketing studies.
• The decision rested on a pivotal trial of about 40,000 participants that found mFlusiva reduced symptomatic flu cases by roughly 27% compared with a standard licensed vaccine.
• Trial participants who received mFlusiva reported higher rates of short‑lived reactions such as injection‑site pain, fatigue, and headache, and investigators identified a small number of serious events judged related to the vaccine, including syncope, a low‑blood‑pressure hospitalization, and one case of perimyocarditis.
• The review process included an unusual early refusal to file the application by a senior FDA vaccines official, a public reversal, a unanimous independent advisory‑panel recommendation in June, and the FDA’s final authorization with required follow‑up studies.
• Public‑health experts say mRNA platforms can allow faster manufacturing and quicker strain updates compared with egg‑based methods, but they stress close monitoring of real‑world effectiveness and safety as Moderna works to supply doses for the 2026–2027 respiratory season.